The Inhibitory Effects of Trastuzumab on Corneal Neovascularization

The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis

“…Also, biomicroscopical examination was performed in their study. Considering the results of this study, no significant difference was observed in terms of burn stimulus, but lower angiogenesis with respect to control group in the trastuzumab-treated group [32]. We also used the same angiogenesis model [14].…”

“…It is known that, after stimulation of EGF-R signaling pathways, ras and raf are activated, resulting in phosphorylation of c-fos and c-jun, which leads to increased AP-1 transcriptional activity [32,33]. Increased AP-1 activity leads to transcription of genes with AP-1 binding sites in their promoter including VEGF and IL-8 [32][33][34]. Experiments in progress are analyzing the effect of EGF-R blockade on the specific transcription factors involved in VEGF and IL-8 regulation in human L3.6pl pancreatic carcinoma cells.…”

“…The mechanisms by which EGF-R signaling pathways regulate VEGF is unclear. It is known that, after stimulation of EGF-R signaling pathways, ras and raf are activated, resulting in phosphorylation of c-fos and c-jun, which leads to increased AP-1 transcriptional activity [32,33]. Increased AP-1 activity leads to transcription of genes with AP-1 binding sites in their promoter including VEGF and IL-8 [32][33][34].…”

Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease

“…Systemic administration of anti-VEGF compounds has also been effective in preventing the alkali burn model of corneal NV in rats. 66 According to 2 recent experimental studies, 67,68 the intraocular (intravitreal or intracameral) routes of bevacizumab injection were found to be more effective in decreasing corneal NV secondary to chemical burn compared with subconjunctival route. This issue, however, has not been yet evaluated in studies on human.…”

Retinal Toxicity of Intravitreal Trastuzumab in a Rabbit Model: Preliminary Results of an Experimental Study

“…9,13,14 Recently, Gü ler et al demonstrated that systemic administration of trastuzumab reduced the extent of experimentally induced corneal neovascularization in a rat model. 15 In consideration of the above, trastuzumab could be also a potential therapeutic approach in the prevention of choroidal or retinal neovascularization.…”